Med. praxi. 2016;13(2):83-88 | DOI: 10.36290/med.2016.018

A patient with hypertension and high cardiovascular risk

MUDr.Jaroslav Brotánek
Ambulance kardiologická, angiologická, interní, Thomayerova nemocnice, Praha

Hypertensive disease is among the most significant risk factors of atherosclerosis in the developed world and represents one of

the causes of premature death worldwide. The management of hypertension in patients with a high cardiovascular risk is a major

issue. Currently, the main goal of hypertension management is to interfere with the renin-angiotensin-aldosterone system. However,

even treatment with RAAS blockers may not always be unequivocal and may have certain pitfalls. The present case report

describes a hypertensive patient with an already developed subclinical organ injury. It illustrates treatment considerations with

respect to the highest possible cardiovascular protection.

Keywords: hypertension, cardiovascular risk, RAAS blockade, ACE inhibitors, sartans, perindopril

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. A patient with hypertension and high cardiovascular risk. Med. praxi. 2016;13(2):83-88. doi: 10.36290/med.2016.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rosolová H, et al. Preventivní kardiologie v kostce. Praha: Axonite 2013.
    2. Colagiuri S. Epidemiology of prediabetes. Med Clin North Am 2011; 95: 299-307. Go to original source... Go to PubMed...
    3. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 Guidelines of the Management of Arterial Hypertension. J Hypertens 2013; 25: 1284-1336.
    4. Mancia G, Laurent S, Agabi-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a Euro-pean Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158. Go to original source...
    5. Widimský J jr., Widimský J, et al. Hypertenze. Praha: Triton, 2014.
    6. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008; 4: 23-36. Go to original source... Go to PubMed...
    7. Van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomised clinical trials of RAAS inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088-2097. Go to original source... Go to PubMed...
    8. Ferrari R, Boersma E. The Impact of ACE Inhibition on All-Cause and Cardiovascular Mortality in Contemporary Hypertension Trials. Expert Rev Cardiovasc 2013; 11(6): 705-717. Go to original source... Go to PubMed...
    9. Souček M. Rozdílný vliv inhibitorů ACE a AT1-blokátorů na mortalitu pacientů: perindopril v terapii hypertenze. Farmakoterapie 2012; 4: 443-448.
    10. Brugts JJ, van Vark L, Akkerhuis M, et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. International Journal of Cardiology 2015; 181: 425-429. Go to original source...
    11. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. J Fam Pract 1996; 42: 577-586.
    12. Stepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307. Go to original source... Go to PubMed...
    13. Souček M. Vliv inhibitorů ACE a sartanů na celkovou a kardiovaskulární mortalitu u pacientů s diabetem: metaanalýza randomizovaných klinických studií. Farmakoterapie 2014; 10(4): 488-490.
    14. Souček M, Kára T, et al. Klinická patofyziologie hypertenze. Praha: Grada 2002.
    15. DiNicolantonio JJ, Lavie CD, O'Keefe JD. Not all Angiotensin-converting enzyme inhibitors are equal: focus on Ramipril and Perindopril. Postgraduate Medicine 2013; 125(4): 154-168. Go to original source...
    16. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 2007; 100(3A): 25J-31J. Go to original source... Go to PubMed...
    17. Tsoukas G, Anand S, Yang K, et al. CONFIDENCE Investigators. Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study. Am J Cardiovasc Drugs 2011; 11: 45-55. Go to original source...
    18. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig 2013; 33: 553-561. Go to original source... Go to PubMed...
    19. Williams B, Lacy PS, Thom SM, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Diferential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225. Go to original source...
    20. Fox KM. The EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source...
    21. Bots ML, Remme WJ, Lüscher TF, et al. ACE Inhibition and Endotelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial. Cardiovasc Drugs Ther 2007; 21: 269-279. Go to original source... Go to PubMed...
    22. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73(1): 237-246. Go to original source...
    23. Rodriguez-Granillo GA, Vos J, Bruining N, et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril's Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159-163. Go to original source...
    24. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48(1): 80-86. Go to original source...
    25. Hui Y, Dai Z, Chen X, et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J Engl 1995; 108: 678-681. Go to PubMed...
    26. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Euro Heart J 2006; 27(19): 2338-2345. Go to original source... Go to PubMed...
    27. Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47 351 hypertensive patients. Br J Clin Pharmacol 1998; 46: 63-70. Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.